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Level of Adenosine Diphosphate Receptor
P2Y12 Blockade During Percutaneous Coronary
Intervention Predicts the Extent of Endothelial Injury,
Assessed by Circulating Endothelial Cell Measurement
Laurent Bonello, MD,*† Karim Harhouri, PHD,† Florence Sabatier, MD, PHD,†§
Laurence Camoin-Jau, MD, PHD,†‡ Laurent Arnaud, PHD,‡ Karine Baumstarck-Barrau, MD,
Omar Ait-Mokhtar, MD,* François Roubille, MD,¶ Christophe Piot, MD, PHD,¶
Nathalie Lesavre, MD,# Franck Paganelli, MD, PHD,* Françoise Dignat-George, MD, PHD†‡
Marseille and Montpellier, France
Objectives We aimed to investigate whether clopidogrel-induced inhibition of platelet reactivity could reduce the level of
circulating endothelial cells (CEC), reflecting the endothelial injury induced by percutaneous coronary interven-
tion (PCI).
Background Clopidogrel loading dose before percutaneous coronary angioplasty (PCI) reduces platelet activation through a
selective and irreversible blockade of the adenosine diphosphate (ADP) receptor P2Y12. The impact of clopi-
dogrel on endothelial cells has been scarcely studied.
Methods A total of 149 patients undergoing PCI for stable angina were enrolled. Levels of CEC were measured at baseline
(H0) and 6 (H6) and 24 (H24) h after the procedure using a CD146-based immunomagnetic separation assay.
The CEC delta-change (CEC at H6  CEC at H0) was analyzed according to ADP receptor P2Y12 blockade, as-
sessed by a vasodilator-stimulated phosphoprotein (VASP) assay after a 600-mg loading dose of clopidogrel.
Results The PCI induced a significant rise in CEC levels 6 h after the procedure. The CEC peak value was significantly
higher in patients with high on-treatment platelet reactivity (VASP index 50%: 59.6  27.5 cells/ml) as com-
pared with good responders (VASP index 50%: 27  22 cells/ml; p  0.04). The endothelial injury, assessed
by CEC delta-change between H6 and H0, was significantly higher in the high on-treatment platelet reactivity
group compared with the good responders group (52.6  25.6 vs. 18.6  23.5, respectively; p  0.001) and
correlated with the VASP index (r  0.59; p  0.001). In multivariate analysis, VASP group, the number of dis-
eased vessels, and the number of implanted stents independently predicted the endothelial injury (p  0.001).
Conclusions Optimal ADP receptor P2Y12 blockade reduces the endothelial injury during PCI. This protective effect of clopi-
dogrel on endothelial cells could add to the clinical benefit associated with this drug. (J Am Coll Cardiol 2010;
56:1024–31) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.072m
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dlatelet interactions with the endothelium participate in the
nitiation and progression of the atherosclerotic plaque (1,2)
nd its complications. In vivo platelet activation not only
nduces thrombus formation but also triggers an inflamma-
ory response responsible for vascular injury and involving
ytokines and chemokines such as chemokine ligand-5 (3),
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September 21, 2010:1024–31 Endothelial Protection by ClopidogrelClopidogrel is a key antiplatelet agent that prevents
hrombotic events in patients with atherothrombosis and
articularly in those undergoing percutaneous coronary
ntervention (PCI) (9). Clopidogrel mainly acts by inducing
selective and irreversible blockade of the adenosine
isphosphate (ADP) receptor P2Y12, thus inhibiting plate-
et aggregation (10). Its effect on ADP receptor P2Y12 can
e selectively and specifically assessed by measuring the ratio
f phosphorylated and dephosphorylated vasodilator-
timulated phosphoprotein (VASP). Determination of the
ASP ratio allows the division of patients into good
esponders (GR), who have a low risk of recurrent throm-
otic event, and patients with high on-treatment platelet
eactivity (HTPR), who have a high risk of an event
ollowing PCI (11–16). Recent studies have reported that in
ddition to its antiplatelet effects, clopidogrel therapy re-
uces the inflammatory response and improves endothelial
unction in patients with coronary artery disease (CAD)
17–19). Moreover, using P2Y12
(/) deficient mice, Evans
t al. (20) demonstrated a role for platelet ADP receptor
2Y12 in the vessel wall response to arterial injury. These
ndings are of critical interest because the endothelium
lays a central role in the maintenance of vascular health by
odulating vasomotor tone, thrombotic, inflammatory, and
ellular proliferation pathways, thus affecting the short- and
ong-term biology of vessel walls. According to the response
o injury theory (21), mechanical damage or chronic expo-
ure to cardiovascular risk factors alters the regulatory
unctions and integrity of the endothelium. As a result,
ndothelial cells detached from injured vessels (22) consti-
ute a hallmark of these deleterious processes. Circulating
ndothelial cells (CEC) are mature endothelial cells that
epresent a noninvasive and specific marker reflecting vas-
ular damage, remodeling, and dysfunction (23–25).
hanks to a consensus definition of CEC and a standard-
zed protocol for identifying these cells (26), there is good
greement among laboratories with regard to CEC counts.
hese cells are present at very low levels in healthy subjects,
hereas elevated levels have been reported in various patho-
ogic situations. Circulating endothelial cells have both a
iagnostic and prognostic significance in CAD (27–29).
revious studies, including some from our group, have
eported that PCI leads to a significant increase in CEC,
eflecting the endothelial injury induced by the procedure
22,30–33). However, the possibility that clopidogrel ther-
py could impact CEC levels has never been investigated
efore. We therefore postulated that ADP receptor P2Y12
lockade induced by clopidogrel loading dose (LD) could
ave a protective effect on endothelium assessed by de-
reased CEC levels.
The aim of the present study was to monitor early
hanges in CEC number in patients undergoing PCI
dentified as GR for clopidogrel compared with HTPR
atients (13). pethods
prospective, multicenter study
as performed. A total of 149
atients undergoing PCI with
are-metal stent implantation for
table angina or silent ischemia
ere enrolled after informed
onsent was obtained. The pro-
ocol was approved by the local
thics committee of Marseille,
ud Mediterranee, and was in
ccordance with the declaration
f Helsinki.
Exclusion criteria were acute
oronary syndrome, drug-eluting
tent implantation, lesion located
n a saphenous vein graft, contra-
ndication to clopidogrel therapy,
leeding diathesis, platelet count
100,000/l, New York Heart
ssociation functional class III or IV, acute or chronic
nflammation, neoplasia, or other concomitant illness
nown to interact with CEC count.
CI. All patients had PCI with bare-metal stent implan-
ation through the radial route using a 6-F sheath. The day
efore the procedure they received an oral LD of aspirin
250 mg) and clopidogrel (600 mg). During the procedure,
bolus of 50 IU/kg heparin was administrated and then
djusted to ensure an activated clotting time between 200
nd 250 s. Glycoprotein IIb/IIIa inhibitors were not used.
he maintenance dose of clopidogrel and aspirin were 75
nd 160 mg, respectively, daily for at least 1 month.
ASP assay. The VASP phosphorylation analysis was
erformed within 24 h of blood collection by an experienced
nvestigator using a platelet VASP kit (Diagnostica Stago,
snières, France) as previously described (11,13–16). Blood
amples were collected 12  2 h after the clopidogrel LD
nd before PCI in all patients. Briefly, blood samples were
ncubated in vitro with ADP and/or prostaglandin E1
PGE1) before fixation. Each sample was indirectly immu-
olabeled by incubation with a 16C2 monoclonal antibody
ollowed by staining with a goat anti-mouse fluorescein
sothiocyanate polyclonal reagent (Stago, Asnières, France).
low cytometric analysis was performed using an EpicsXL
ytometer (Beckman Coulter, Inc., Fullerton, California).
latelet population was identified on its forward and side
catter distributions, and 3,000 platelet events were gated
nd analyzed for mean fluorescence intensity using EpicsXL
oftware. Mean fluorescence intensity (MFI) corresponding
o each experimental condition (ADP or ADP  PGE1) was
etermined to establish a ratio directly correlated with
ASP phosphorylation state. The ratio, 100  ([MFIPGE1 
FIADP  PGE1]/MFIPGE1), is expressed in this study as a
ASP index corresponding to a ratio of the VASP phos-
Abbreviations
and Acronyms
ADP  adenosine
disphosphate
BMI  body mass index
CAD  coronary artery
disease
CEC  circulating
endothelial cell(s)
GR  good responders
HTPR  high on-treatment
platelet reactivity
LD  loading dose
MFI  mean fluorescence
intensity
PCI  percutaneous
coronary intervention
VASP  vasodilator-
stimulated phosphoproteinhorylation of activated platelets versus at-rest platelets and
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Endothelial Protection by Clopidogrel September 21, 2010:1024–31s expressed as a percentage of platelet reactivity. The
ntra-assay coefficient of variation was 5%, and the inter-
ssay coefficient of variation was 8%. This test provides a
tandardized, reproducible, and specific measure of ADP
eceptor P2Y12 blockade activity. Based on previous studies
inking the VASP index to a clopidogrel LD and clinical
utcome, we divided the patient population into 2 groups
sing a cut-off value of 50% of post-treatment platelet
eactivity: GR with a VASP index 50% and patients with
TPR with a VASP index 50% (11,13–16).
numeration of CEC. Four milliliters of blood were
ollected into EDTA by venipuncture of the antecubital
ein, immediately before (H0) and 6 (H6) and 24 (H24) h
fter PCI. As previously reported, these sample times allow
onitoring of the peak level of CEC increase reflecting the
ndothelial damage induced by PCI (32). The CEC were
ounted according to a standardized protocol (26). Briefly,
he first 2 ml of drawn blood was discarded to avoid
ontamination by mural endothelial cells dislodged by the
enipuncture. The CEC were counted by an operator
naware of the patients’ clinical features. Immunoseparation
f CEC from blood was performed at 4°C with magnetic
eads (Dynabeads M-450, Invitrogen, Carlsbad, California)
oated with S-Endo1 (Biocytex, Marseille, France), a
onoclonal antibody directed against the endothelial anti-
en CD146. To avoid nonspecific binding of leukocytes to
D146-coated beads, the cell suspensions were flushed
igorously through a pipette tip during the washing steps
nd then suspended in acridine orange (3 g/ml in
hosphate-buffered saline, Sigma-Aldrich, Saint-Quentin
allavier, France) before being counted under a fluorescence
icroscope. The CEC were identified according to the
ollowing consensus morphologic and immunologic criteria:
osetted cells with sizes of 20 to 50 m and bearing more
han 10 beads or bearing fewer than 10 beads but with
ell-preserved and recognizable morphology (clear nucleus
n a well-delineated cytoplasm) and Ulex europeaus lectin-1
inding. The number of CEC was expressed as cells/ml of
lood.
tatistical analysis. The CEC delta-change (CEC at
6  CEC at H0) was calculated to measure the endothe-
ial injury induced by PCI independently from CEC base-
ine level (32). Comparisons between both groups were
erformed using Student t tests for quantitative variables
nd chi-square or Fisher exact tests for frequencies. The
tudent t test for paired samples was used to compare CEC
eans before and 6 h after PCI in each group. Associations
etween continuous variables were analyzed using Pearson
orrelation tests. Multivariate analyses using multiple linear
egressions were performed to determine variables poten-
ially related to CEC delta-change. Variables relevant to the
odels were selected based on a threshold p value 0.2 in
nivariate analysis (hypertension, diabetes, family history of
AD, VASP group [GR and HTPR], number of diseased
essels, and number of stents) and/or their clinical interest
age, sex, body mass index [BMI], statin therapy, and ospirin). The final model expressed the standardized beta
oefficient, which represents the change in SD units in the
ependent variable resulting from a change of 1 SD in the
ifferent independent variables. All of the tests were
-sided. Statistical significance was defined as p  0.05.
tatistical analysis was performed using the SPSS version
5.0 software package (SPSS, Inc., Chicago, Illinois).
esults
aseline characteristics of GR and HTPR patients. The
nal sample included 149 patients, corresponding to 61 GR
atients and 88 patients with HTPR. Patient characteristics
re displayed in Table 1. The GR group included 61 (41%)
atients, whereas the HTPR group comprised 88 (59%)
atients. The mean VASP index was 23.7  12.5% in the
R group and 65.1  9.7% in the HTPR group. The 2
roups of patients were similar in age and sex ratio.
egarding cardiovascular risk factors, the prevalence of
iabetes and BMI were significantly higher in the HTPR
roup compared with the GR group (31.8% vs. 8.2%, p 
.001 and 27.3 4.9 kg/m2 vs. 25.4 4.3 kg/m2, p 0.02,
espectively), whereas prevalence of smoking, hypertension,
yslipidemia, and family history of CAD was similar in both
roups. No significant difference was found among medi-
ations on admission (including clopidogrel chronic ther-
omparison of Baseline Characteristicsf GR and HTPR GroupsTable 1 Comparison of B seline Characteristicsof GR and HTPR Groups
GR
(n  61)
HTPR
(n  88) p Value
Age (yrs) 64.4 12.5 64.8 10.9 0.82
Women 18 (29.5) 18 (20.5) 0.25
Cardiovascular risk factors
BMI (kg/m2) 25.4 4.3 27.3 4.9 0.02
Smoker 17 (27.9) 26 (29.5) 0.86
Hypertension 32 (52.5) 51 (58.0) 0.62
Diabetes 5 (8.2) 28 (31.8) 0.001
Dyslipidemia 32 (52.5) 59 (67.0) 0.09
Family history of CAD 19 (31.1) 18 (20.5) 0.18
Medications
Statins 37 (60.7) 56 (63.6) 0.73
Aspirin 23 (37.7) 48 (54.5) 0.05
Clopidogrel 32 (52.5) 42 (47.7) 0.62
Beta-blocker 33 (54.1) 41 (46.6) 0.41
Intervention
No. of diseased vessels 1.8 0.8 1.7 0.8 0.37
No. of stents 1.9 1.0 1.6 0.9 0.09
Stent diameter (mm) 3.1 0.4 3.1 0.4 0.55
Stent length (mm) 21.9 11.1 23 13 0.58
Biology
Hemoglobin (g/dl) 13.3 1.2 13.5 1.3 0.30
White blood count (g/l) 7.1 2.2 9.0 12.6 0.25
Platelets (103/mm3) 215 46 228 67 0.21
Creatinine (mol/l) 83.4 31.1 79.9 26.4 0.49
Fibrinogen (g/l) 3.4 0.9 3.5 0.9 0.54
alues are mean  SD or n (%).
BMI  body mass index; CAD  coronary artery disease; GR  good responders; HTPR  high
n-treatment platelet reactivity.
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September 21, 2010:1024–31 Endothelial Protection by Clopidogrelpy) and baseline laboratory data between the 2 groups.
ngiographic and interventional data were also similar in
he 2 groups, including the number of diseased vessels.
EC increase induced by PCI is reduced in GR patients
nd correlated to the level of ADP receptor P2Y12
lockade. The endothelial injury induced by PCI was
onitored by CEC counts determined at H0, H6, and
24. The kinetics of CEC released from the vessel wall is
isplayed in Figure 1. No significant difference in pre-
rocedural CEC counts was observed between GR and
TPR patients (8.3  8.8 cells/ml vs. 6.8  8 cells/ml,
espectively; p  0.3). Consistent with the inclusion criteria
imited to patients with stable CAD, these baseline values
ere low and within expected normal range (31). In both
roups of patients, PCI induced a significant rise in CEC
evels detectable 6 h after the procedure compared with
re-procedural values (GR and HTPR groups: 26.9  22.5
ells/ml vs. 8.3  8.8 cells/ml, p  0.0001 and 59.6  27.5
ells/ml vs. 6.8  8 cells/ml, p 0.0001, respectively).
nterestingly, the CEC peak value was significantly higher
n the HTPR group compared with the GR group (59.6 
7.5 cells/ml vs. 27  22 cells/ml, p  0.001). Twenty-four
ours after the procedure, although CEC levels had signif-
cantly decreased compared with peak values in both groups,
significant difference was still observed compared with
aseline (16.3  18.3 cells/ml, p  0.003 and 20.6  13.1
ells/ml, p  0.001, respectively, for GR and HTPR)
Fig. 1). The extent of endothelial injury was assessed by the
ifference in CEC count between H6 and H0, which
efined CEC delta-change. This CEC delta-change evalu-
tes the impact of the procedure independently from base-
ine CEC level (29). Interestingly, the endothelial injury
ssessed by CEC delta-change was significantly higher in
Figure 1 CEC Levels in GR and HTPR Patients
The circulating endothelial cells (CEC) levels were determined using a CD146-
based immunomagnetic separation assay in good responders (GR) (VASP index
50%) and high on-treatment platelet reactivity (HTPR) patients (vasodilator-
stimulated phosphoprotein [VASP] index 50%) before and 6 and 24 h after
percutaneous coronary intervention. Results are mean  SD cells/ml. ***p 
0.001 compared with baseline value between groups. §p  0.001 between GR
and HTPR patients.TPR compared with GR patients (52.6 25.6 vs. 18.6
3.5, respectively; p  0.001) (Fig. 2). In addition, a
ignificant correlation between the VASP index and CEC
elta-change (r  0.59; p  0.001) was observed in the
tudy population, indicating that patients with the higher
DP receptor P2Y12 blockade had the lower endothelial
njury (Fig. 3).
DP receptor P2Y12 blockade is an independent predictor
f CEC increase during PCI. A linear regression analysis
as used to determine predictors of endothelial injury
ollowing PCI. The univariate analysis showed that the
ASP group (GR and HTPR), family history of CAD, and
he number of stents were significantly associated with the
ndothelial injury (Table 2). However, after adjustment for
Figure 2 Comparison of CEC Delta-Change
Between GR and HTPR Patients
The CEC delta-change is the CEC value 6 h after PCI  CEC value
at baseline. Results are means  SD cells/ml. Abbreviations as in Figure 1.
Figure 3 Correlation Between CEC Delta-Change
and VASP Index
Abbreviations as in Figure 1.
a
t
n
i
a
n
s
w
s
i
a
c
D
T
o
l
t
t
C
V
i
c
a
r
i
o
s
s
p
i
A
a
a
s
s
i
h
c
r
i
b
l
o
i
(
d
v
(
r
i
d
p
Uf
*
c
v
CEC  circulating endothelial cells; VASP  vasodilator-stimulated phosphoprotein; other
abbreviations as in Table 1.
1028 Bonello et al. JACC Vol. 56, No. 13, 2010
Endothelial Protection by Clopidogrel September 21, 2010:1024–31ge, sex, BMI, hypertension, diabetes mellitus, family his-
ory of CAD, statin therapy, number of disease vessels, and
umber of stents implanted, the multivariate approach
dentified 3 independent predictors of endothelial injury
ssessed by CEC delta-change: VASP group (p  0.001),
umber of diseased vessels (p  0.009), and number of
tents implanted (p  0.046) (Table 2). These 3 parameters
ere similarly linked to CEC peak values (H6) (data not
hown). Altogether, these data indicated that disease sever-
ty, mechanical trauma, and ADP receptor P2Y12 blockade
re independent predictors of the endothelial injury in
lopidogrel-treated patients undergoing PCI.
iscussion
o our knowledge, this is the first prospective study dem-
nstrating a protective effect of clopidogrel on the endothe-
ium during PCI. Indeed, a correlation was found between
he level of ADP receptor P2Y12 blockade, as measured by
he VASP index, and the endothelial injury, assessed by
EC peak values and delta-change. In multivariate analysis,
ASP group, number of diseased vessels, and number of
mplanted stents independently predicted CEC delta-
hange, indicating that ADP receptor P2Y12 blockade was
n independent determinant of the endothelial injury.
Clopidogrel is widely used in patients with CAD to
educe the risk of thrombotic events. Interestingly, a large
nterindividual variability in response to the drug has been
bserved in patients with CAD (14,34). Of importance,
everal investigators have since reported a strong relation-
hip between the response to clopidogrel and occurrence of
ost-PCI thrombotic events (11–16,35,36). The VASP
ndex is the most specific platelet assay to evaluate P2Y12
DP receptor blockade and is not influenced by other
ntiplatelet agents or anticoagulants (37). Therefore, the
ssessment of ADP receptor P2Y12 blockade, which repre-
ents the biologic effect of the drug, is also of clinical
ignificance. In fact, the 50% cut-off value of the VASP
ndex used in the present study was shown to have a very
igh negative predictive value for major adverse cardiovas-
ular events (11–16). Using the same threshold of platelet
eactivity, we found that optimal clopidogrel responsiveness
s associated with reduced CEC elevation following PCI.
Increased levels of CEC have been identified across a
road spectrum of cardiovascular diseases and have been
inked to the clinical severity, as well as the clinical outcome,
f CAD (24). Several studies have highlighted the interest
n the early evaluation of endothelial damage following PCI
30–32). We have previously reported that CEC elevation is
etectable as early as the end of the procedure, whereas peak
alues are observed 6 h after the end of the intervention
32). These kinetics indicate that CEC increase not only
eflects the direct mechanical injury related to balloon
nflation and stent deployment but also more widespread
eleterious responses related to inflammation or ischemianivariate and Multivariate Analysisor Predictors of CEC Del a-Ch ngeTable 2 Univariate and Multivariate Analysisfor Predictors of CEC Delta-Change
Univariate
Analysis
Multivariate
Analysis
CEC H6  H0,
Mean  SD or R* p Value Beta† p Value
Age (yrs) 0.07 0.42 0.009 0.907
Sex
Women 37.9 29.9 0.76 0.068 0.384
Men 39.8 29.8
Cardiovascular risk factors
BMI (kg/m2) 0.08 0.38 0.016 0.849
Smoker
Yes 40.5 29.5 0.79
No 38.9 30.0
Hypertension
Yes 43.2 30.8 0.10 0.114 0.171
No 34.8 28.0
Diabetes
Yes 48.2 33.0 0.06 0.023 0.782
No 36.7 28.3
Dyslipidemia
Yes 39.8 27.7 0.82
No 38.7 32.8
Family history of CAD
Yes 28.6 28.7 0.02 0.065 0.423
No 42.9 29.4
Medication
Statins
Yes 37.7 29.5 0.41 0.139 0.146
No 42.1 30.3
Aspirin
Yes 40.8 29.3 0.58 0.021 0.825
No 38.0 30.3
Clopidogrel
Yes 39.1 29.8 0.92
No 39.6 29.9
Beta-blocker
Yes 38.8 28.6 0.82
No 40.0 31.1
Intervention
No. of diseased vessels 0.12 0.18 0.219 0.009
No. of stents 0.17 0.05 0.169 0.046
Stent diameter (mm) 0.10 0.28
Stent length (mm) 0.03 0.73
Biology
Hemoglobin (g/dl) 0.05 0.59
White blood count (g/l) 0.05 0.55
Platelets (103/mm3) 0.03 0.79
Creatinine (mol/l) 0.05 0.61
Fibrinogen (g/l) 0.11 0.21
VASP group
GR (VASP 50%) 18.9 23.5 0.001 0.514 0.001
HTPR (VASP 50%) 52.6 25.6
R Spearman correlation coefficient. †Beta standardized beta coefficient (beta represents the
hange of the SD in quality of life score resulting from a change of 1 SD in the independent
ariable).articipating in delayed endothelial detachment (38,39). In
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September 21, 2010:1024–31 Endothelial Protection by Clopidogrelddition, we have previously observed CEC released from
uptured plaques in acute coronary syndrome, and their
rognosis values have been documented (27–29). Given the
ey role of endothelial denudation in atherothrombosis,
hese data indicate that reduced endothelial vulnerability
videnced by CEC levels may participate in the clinical
enefit of clopidogrel over recurrent thrombotic events. In
ddition, these findings may be of particular interest in
atients undergoing drug-eluting stent implantation be-
ause of the relationship between endothelial damage and
rug-eluting stent thrombosis (40).
Comparison of baseline characteristics of the 2 subgroups
f patients indicated that they differed according to BMI
nd the number of patients with diabetes mellitus. These
bservations are consistent with previous reports of an
ssociation between these clinical factors and reduced re-
ponsiveness to antiplatelet agents (31–42). In addition,
iabetes has already been associated with high numbers of
EC (43). However, the possibility that these risk factors
mpact the difference observed in CEC level post-PCI was
uled out by multivariate analysis. Determination of factors
nfluencing CEC delta-change evidenced the role of clopi-
ogrel responsiveness. ADP receptor P2Y12 blockade was
hown to independently predict CEC delta-change or peak
evel, demonstrating a protective effect of clopidogrel-
ependent inhibition of platelet reactivity on endothelial
amage during PCI. The mechanisms underlying the pro-
ection of the endothelium by clopidogrel remain to be fully
lucidated. In line with the hypothesis of a beneficial
eduction of endothelium-platelet interactions, short-term
lopidogrel treatment in patients undergoing PCI has been
hown to limit agonist-induced platelet P-selectin and
D40L expression and subsequent release of inflammatory
ediators like tumor necrosis factor known to participate in
EC release (44,45). Similarly, the link between inhibition
f platelet function and reduction of various inflammatory
arkers has been recently demonstrated during long-term
lopidogrel treatment (46). In addition, improvement of
ndothelial function in patients with CAD under chronic
lopidogrel therapy has been shown to occur concomitantly
ith a reduction of the oxidative stress marker 8-iso-
GF2alpha and inflammatory markers such as high-
ensitivity C-reactive protein and sCD40L (19).
Beside platelet-dependent mechanisms, findings from
nimal models and in vitro studies have identified platelet-
ndependent effects of thienopyridines on the vasculature.
hese effects included a desensitization of aortic rings to
asoconstrictors after intravenous administration of clopi-
ogrel (47) and a dose-dependent increment of nitric oxide
roduction in ECV304 cells incubated with clopidogrel
48). Finally, the recently described expression of ADP
eceptor P2Y12 by human coronary endothelial cells and
UVEC (49) allows us to hypothesize that clopidogrel
ould also impact the endothelium by direct interaction with
n endothelial receptor. More insight into the targets of
DP receptor P2Y12 blockade was evidenced using a modelf arterial injury in bone marrow–transplanted chimeric
ice, which showed that reduced vessel wall response to
njury in P2Y12-deficient mice was mainly dependent on
latelet ADP receptor P2Y12 blockade (20).
tudy limitations. Limitations of the present study include
he lack of outcome data and the slightly higher rate of
atients considered to have HTPR compared with that in
revious studies.
In the present study, we observed that, in addition to the
evel of ADP receptor P2Y12 blockade, the number of
iseased vessels and number of implanted stents were also
ndependently associated with the endothelial injury. These
ata indicate that, besides platelet reactivity, disease severity
lso determines endothelial vulnerability to PCI and is
onsistent with increasing endothelial dysfunction in ad-
anced CAD (50). Moreover, the CEC increase is also
ependent on the number of implanted stents, in line with
he critical role of mechanical trauma in endothelial detach-
ent (51). Altogether, these data suggest that CEC in-
rease may be a reliable marker integrating the impact of
rocedural and clinical risk factors together with platelet
eactivity on endothelial vulnerability during PCI, with
otential prognostic significance.
onclusions
he present study demonstrated that the level of ADP
eceptor P2Y12 blockade induced by clopidogrel reduces the
ndothelial injury after PCI. Because disruption of endo-
helial integrity promotes thrombosis and restenosis, which
epresent the main limitations of PCI, the findings suggest
hat optimized ADP receptor P2Y12 blockade may reduce
ascular events, not only by preventing acute thrombosis but
lso by exerting protective endothelial effects.
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